This small pharmaceutical company was in a race to be first to market for diarrhea-predominant Irritable Bowel Syndrome (IBS), a market with multi-billion dollar potential. An 11-month enrollment timeline was critical to the successful completion of a two-protocol, phase III program.
We make gastroenterology trials less painful…and easier to digest.
Our success is a combination of aligning the enrollment process with today’s realities, customized solutions, and true insight into site relationships. From OIC/OIBD, IBS and GERD, to Crohn’s disease, Acurian makes trials a lot less trying.
Acurian is the leader in the patient recruitment and retention industry.
Acurian has recruited and enrolled thousands of patients for more than 60 pharmaceutical and biotech companies representing over 4,500 research sites.